Image Image Image Image Image
Scroll to Top

To Top

Featured

06

Apr
2020

In Blog
Featured

By admin

Defense, and SAb Biotherapeutics to Partner to Develop a Novel COVID-19 Therapeutic

On 06, Apr 2020 | In Blog, Featured | By admin

Published by Medical Counter Measures

A therapeutic to treat novel coronavirus disease 2019 (COVID-19) is moving forward in development through a partnership between BARDA, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO – CBRND), and SAb Biotherapeutics, Inc. (SAb), of Sioux Falls, South Dakota.

Using an interagency agreement with JPEO’s Medical CBRN Defense Consortium, BARDA transferred approximately $7.2 million in funding to (JPEO – CBRND) to support SAb to complete manufacturing and preclinical studies, with an option to conduct a Phase 1 clinical trial.

Read the full press release here.

30

Mar
2020

In Blog
Featured

By admin

Agri-Pulse: Can cows be used to fight coronavirus?

On 30, Mar 2020 | In Blog, Featured | By admin

Bovine plasma donors genetically engineered to produce human antibodies are in the front lines of the struggle against coronavirus.

SAB Biotherapeutics, a Sioux Falls, S.D., biotechnology company that has been successfully testing use of antibodies from cows to fight diseases such as another coronavirus, Middle East respiratory syndrome, now is engaged in developing a treatment for COVID-19, the disease caused by the novel coronavirus.

Read the full article here.

07

Nov
2019

In Blog
Featured

By admin

Times Argus: High-tech chestnuts: US to consider genetically altered tree

On 07, Nov 2019 | In Blog, Featured | By admin

SYRACUSE, N.Y. (AP) — Chestnuts harvested from high branches on a chilly fall morning look typical: they’re marble sized, russet colored and nestled in prickly burs. But many are like no other nuts in nature.

In a feat of genetic engineering, about half the chestnuts collected at this college experiment station feature a gene that provides resistance to blight that virtually wiped out the American chestnut tree generations ago.

Read more here.

25

Apr
2019

In Blog
Featured
GMO’s and The Environment

By admin

Farm to Food Gene Editing: The Future of Agriculture

On 25, Apr 2019 | In Blog, Featured, GMO’s and The Environment | By admin

Curious about what gene editing is? Watch this video to learn how CRISPR is helping farmers grow better crops to feed our growing population.

23

Apr
2019

In Blog
Featured
GMO’s and The Environment

By admin

USA Today: Earth Day for a dairy farmer: Thinking decades down the line

On 23, Apr 2019 | In Blog, Featured, GMO’s and The Environment | By admin

What U.S. dairy farmers of today are doing to preserve our environment

I’ve had the honor of working with dairy farmers for years, and a lot of what you think about them is true. They’re modest. They’re connected to the earth. And they work incredibly hard. Every day, they’re up before dawn, working 12 and 14-hour days, whether it’s 90 degrees out or 50 degrees below zero.
 
They choose this hard work because they believe in the importance of providing nutritious, great-tasting food, like the milk in your child’s glass or the slice of cheese on her favorite sandwich.

Read more here.


27

Nov
2018

In Blog
Featured

By admin

Science makes bread taste better

On 27, Nov 2018 | In Blog, Featured | By admin

Renegade bakers and geneticists develop whole-wheat loaves you’ll want to eat

BY VERONIQUE GREENWOOD BOSTON GLOBE

riving up through the rolling farmland north of Seattle this July, I was thinking about my next meal. I arrived in the small industrial park, home to the Washington State University Bread Lab, for a gathering of wheat geneticists and other grain professionals. I’d missed the explanation of the items on the buffet tables, made by attendees. I loaded my plate with about a pound of cookies from the dessert end and steadily consumed the lot. They were soft and nutty, with a rich ruddy color and a delicate crumb. I wiped buttery crumbs from my fingers. I went back for more.

“What are these?” I asked the volunteer by the coffee pots, brandishing a blondie bar. “I’m not sure,” she said. They must be made from some delicious heirloom grain, or something, I thought, surreptitiously loading my pockets.

They’re whole wheat, the lab’s head, Stephen Scott Jones, later told me. One hundred percent. That was a surprise; whole wheat baked goods are often eaten more out of obligation than pleasure. They are not known for their can’t-stop-eating flavor. And yet, the Bread Lab is making its name by doing something that is almost unique in the industry: Breeding wheat — especially wheat for whole wheat flour — for taste. They and their collaborators across the country have quietly launched an effort that they hope will create something new — a whole wheat loaf that people would actually like to eat.

Wheat breeders who develop new strains for the global market aim for traits like the right height for mechanized harvesting, the right texture for mechanized baking, and a high yield. As odd as it sounds, flavor more or less faded from breeders’ awareness somewhere along the line. Jones says that for most of his decades-long career as a breeder, it was not discussed. At the same time, knowledge of the importance of whole grains has been on the rise: Eating whole wheat and other unrefined grains correlates with better heart health, healthier weight, and even longer life, according to epidemiological studies.

So maybe the time is right. At the Bread Lab’s headquarters this summer, a plucky group of about 40 bakers, millers, breeders, and others met to test-bake a loaf they’ve been discussing and fine-tuning for the last two years. They call it the Approachable Loaf.

The loaf they’re all dreaming of has a simple recipe. Start, first of all, with the right wheat for the job. The lab grows thousands of newly generated strains of wheat every year to test them. Steve Lyon, the Bread Lab’s head technician, took me out to one of the experimental fields this summer, where the stalks stood in a patchwork of yellows and tans, all different heights and shapes. The researchers make the same basic test loaf from the freshly milled flour — whole wheat goes rancid quickly, so using fresh-milled is important — and then they taste it. They have identified one new wheat, which they’ve dubbed Skagit 1109, that makes a reliably tasty whole wheat bread. For the moment, a bakery making the Approachable Loaf will likely have to use commodity wheat, but ideally, they’ll develop better options.

The story of bread as we’ve known it is the story of our food system as a whole: In the 19th and 20th centuries, the advance of technology on farms, in mills, and in factories allowed the mass production of foods from an ever-longer list of ingredients, both natural and artificial. The Approachable Loaf symbolizes something else — the possibility that, through the application of science, even a food as humble and maligned as whole wheat bread can be both simpler and tastier.

Nutritionally, whole wheat flour is better for you than white. The germ and the bran, the portions of the wheat kernel with the most fiber and other nutrients, stay in whole wheat flour when it’s milled, giving it its distinctive dark color. But they usually curb your desire to put it in your mouth. Compared to the seductive quality of a good white sourdough — tangy and just a little stretchy — or even the gentle squish of a soft white grocery store loaf, melting seamlessly into a slab of grilled cheese, the ashy, faintly bitter whole wheat loaf is no competition.

The battle between light and dark in the matter of bread is longer and weirder than most people realize. While many might assume the rise of whole wheat bread as a health food started with the counterculture of the 1960s and ’70s, anthropologist Aaron Bobrow-Strain traces it back far earlier. Over thousands of years, the color of bread has carried various meanings, he writes in his book “White Bread: A Social History of the Store-Bought Loaf.” Hearty dark loaves were better for building a society than wimpy white ones, Plato argued in “The Republic”; Socrates, on the other hand, felt whole-meal bread was essentially animal food.

By the 19th century in the United States, activists claimed whole wheat would bring people closer to God, and thus to health. One influential obsessive was Sylvester Graham, the New England minister who gave his name to the graham cracker. A sickly child, he eventually turned to vegetarianism as an adult. Today, he might have started a blog about clean eating. Eating foods in their most natural form, like whole wheat, was what God intended man to do, Graham argued in lectures that caused riots in Boston and New York, and anything that was wrong with you could be taken care of with whole wheat bread and water.

Grahamism had adherents of all stripes: Educational reformer Amos Bronson Alcott, father of Louisa May Alcott, the author of “Little Women,” founded a farm commune northwest of Boston to live in the manner prescribed by the movement. It lasted only seven months. Louisa May, who was 10 at the time, later lampooned the endeavor in her satire “Transcendental Wild Oats.” She noted that the vast majority of the labor fell to women and children, while the men sat around discussing the philosophy of food. “About the time the grain was ready to house,” she wrote dryly, “some call of the Oversoul wafted all the men away.”

Today, the benefits of eating more whole grains are among the rare things that virtually all nutrition experts agree on. The US Dietary Guidelines Advisory Committee recommends that half of all grains should be whole. But 2015 numbers show that almost nobody eats that way.

Past efforts to make virtue a little tastier have achieved the opposite. The food historian Maria Trumpler visited the Bread Lab recently and demonstrated whole wheat bread recipes from the 1970s and ’80s — an era when adding molasses, powdered milk, and other substances to try to hide the whole wheat was in vogue.

“They were just absolutely horrible,” says Jones, nearly awed by the badness. “If you have a bread book from the ’70s, you should burn it! I’m not into book burning, but, God — you should just get rid of it.” There must, he and colleagues think, be a better way.

Wheat breeder David Van Sanford, a professor at University of Kentucky, recalls when he first learned of Jones, who had become fed up with the situation and helped found the Bread Lab in 2011. I’ve gone to scads of meetings, Jones had told a reporter, and never heard the term “flavor” used once. “That really resonated with me,” Van Sanford says. Wheat flour can, in fact, have a taste: For a good bread wheat, “the words we use are nutty, chocolate tones, and a bit of spice tone,” Jones says. A wheat used for cookies and pie dough has a different, more mellow profile.

When most wheat breeders assess the outcomes of their efforts and decide what to do next, however, they evaluate what the wheat is like without the bran and germ. The bran and the germ are what give whole wheat much of its taste. As a result, a wheat that’s bred for an inoffensive-tasting white flour might make a whole wheat flour that’s depressingly like sawdust. When no one is breeding for a whole wheat that tastes good, Jones argues, it is not all that surprising that it winds up bad. Jones’s savvy as a scientist and his conviction are persuasive; his lab has relationships with well-known companies such as King Arthur Flour, Clif Bar, and Chipotle.

If a whole wheat loaf has a good flavor, is affordable, and meets the needs of those who don’t frequent artisanal bakeries — which have a dedicated but small clientele — it wouldn’t be nearly so hard for people to eat more of it, think the people behind the Approachable Loaf, many of whom have attended annual gatherings at the Bread Lab over the last few years.

One of them, Louie Prager, who runs the Prager Brothers bakery in Carlsbad, Calif., has noticed that some of his own employees prefer a soft brown supermarket loaf. It has no holes for mustard to leak through, it’s good for sandwiches for packed lunches, it doesn’t go bad very quickly, it’s familiar, and it’s inexpensive, something you can’t say about some artisanal loaves. But it often has many stabilizers, colorants, and dough conditioners that artisan bakers avoid, as well as a surprising amount of sugar.

Other than better wheat, the only other ingredients in the Approachable Loaf are sourdough starter, salt, small amounts of oil and sugar, and water. Using starter to leaven the bread gives it a longer shelf life than a standard yeasted bread; the sugar and oil give the bread a flavor and texture that’s closer to the supermarket loaf.

Experience and skill on the part of the baker helps in getting a good product, of course: Those bizarrely delicious cookies I tasted at the Bread Lab’s headquarters did involve a good choice of wheat, but the flour was also probably freshly milled and the bakers knew what they were doing, notes Van Sanford. The loose network of people testing and fine-tuning the Approachable Loaf includes professional bakers in Washington, California, and Vermont, working to bring their technical knowledge of artisanal bread making to bear on something closer to the supermarket loaf. Jones estimates that at least eight bakeries are currently making some version of it.

Can the Approachable Loaf go big? Bringing together breeding, farming, processing, and food production to make something that both satisfies the consumer and is nutritious is not a simple process, says Tim Griffin, a professor at the Friedman School of Nutrition Science and Policy at Tufts University who collaborates with Bread Lab researchers. But for the past year and a half or so, he and colleagues have been discussing it in the context of the Approachable Loaf. “We’re seeing bread as our first test case for that,” he says. “What would the system have to look like if we successfully used whole grains?” They are investigating what businesses would need to exist, how the supply chains for bread would need to change, and other logistical barriers to a loaf that’s both nutritious and legitimately attractive.

If the bakers can come up with a tasty loaf, then the millers will need to come up with a procedure to mill large quantities of whole wheat flour while keeping it from going bad, and farmers will need to learn to grow and profit from breeds of wheat that make whole wheat worth eating. These are the kinds of challenges he’s considering.

In Montana, wheat breeder and Flathead Valley Community College professor Heather Estrada has her eyes on the near term: using wheat she and her students have grown to bake the Approachable Loaf together. “We were able to clean all our grain and it’s ready for milling,” she said gleefully when I spoke to her October. The loaf is a way for her students to see all the pieces of the food system they’ve been studying all semester, from field to lab to kitchen, come together in a way that’s more than glancing. “There’s a lot of cultural depth,” Estrada says, “to the story of bread.”

http://apps.bostonglobe.com/ideas/graphics/2018/11/the-next-bite/the-seeds/

26

Nov
2018

In Blog
Featured
GMO Labeling
GMO’s and The Environment

By admin

Boston Globe: 3 policies for the future

On 26, Nov 2018 | In Blog, Featured, GMO Labeling, GMO’s and The Environment | By admin

Food is going high-tech — policy needs to catch up with it

BY THE BOSTON GLOBE EDITORIAL BOARD

or generations newspaper editorials have been the “eat your spinach” part of the operation. But what if that spinach can now be organic baby spinach, or hydroponically grown? What if we can eat it year round — and from just around the corner?

With a warming planet, the need for high-tech food and high-tech food policies is undeniable. Both are going to play an increasingly vital role in the planet’s future — and the way we eat. Here are a few ways to use science to steer food into a more sustainable path.

Learn to love GMOs, and resist efforts to demonize or prohibit them. Genetically modified food sets off alarm bells for purists, but crops designed to last longer or resist disease are increasingly necessary.

The good news is that new federal labeling regulations, which could become final by Dec. 1, will preclude the kind of state-by-state labeling regulations that Vermont had already indulged in and that Massachusetts has been perpetually on the cusp of enacting.

The even better news is that the science of food — of producing fruits with a longer shelf life, wheat that requires less water or fertilizer — is advancing so fast that even the foodie fearmongers can’t keep up.

First on the federal role: While moving at a glacial pace, the US Department of Agriculture has at long last brought forth a final set of regulations designed to implement a law passed by Congress in 2016 to deal with standards for disclosing bioengineered ingredients. Not surprisingly the new regs generated a huge amount of controversy — more than 14,000 comments received by the agency during the public comment period.

Assuming the regs are indeed finalized Dec. 1, they won’t go into effect until Jan. 1, 2020. What consumers are likely to notice is that GMO labeling will become “BE food,” or “bioengineered food.” And since at least two-thirds of all foods sold in the US contain some ingredients in that category — consumers are indeed likely to see it everywhere.

What it will accomplish is to prevent every state and locality from drafting its own labeling laws and, in the process, making the free movement of good products from state to state difficult if not impossible. And it will let innovation continue unhindered.

The future of seafood in the United States is aquaculture. Even the king of seafood, Roger Berkowitz, acknowledges that. “The technology has gotten so good with submersible pens,” said Berkowitz, chief executive of the Legal Sea Foods empire. “It’s a game changer.”

Berkowitz is particularly excited about the prospect of fish farms in federal open waters. Aquaculture in Massachusetts is largely confined to shallow waters; think oyster beds on Cape Cod. Of course, this country for years has talked about offshore fish farming, but the time has come, with wild fish stocks dwindling. In 2017, the US imported a record amount of seafood, more than 6 billion pounds, and exported only about 3.6 billion pounds.

While Massachusetts and some municipalities have regulated aquaculture, what’s needed now is a federal regulatory framework to support aquaculture in the ocean. It hasn’t been easy navigating the concerns of environmentalists, fishermen worried about their own livelihoods, and ships attached to particular routes. The ocean may be big, but surprisingly not big enough to accommodate everyone’s needs.

Congress can play a big role: Get a bill that everyone likes. Here’s another thought: How about supporting aquaculture as part of the farm bill, something US Representative Seth Moulton would like to see. With Democrats taking back the majority in the House, maybe this could get done next year.

Clear federal policies could enable the prospect of fish farming using the infrastructure of offshore wind turbines. Without such policies, the future of fish farming will remain murky, because these operations are expensive and investors don’t like uncertainty.

“No one would spend a dime on that,” said Peter Shelley, senior counsel at the Conservation Law Foundation, which has been closely following the development of aquaculture in the ocean. “It makes Cape Wind look like a sure bet.”

Assume change. Farm and food policies tend to deal with what we eat and grow now, but climate change should end that way of thinking. The government and industry need to anticipate disruption, and be ready to adapt, rather than pour money into trying to preserve vanishing industries that can’t be sustained any longer.

Rising temperature of oceans, for example, have forced the cod and lobsters to flee north to colder waters. We lament the loss of cod in Massachusetts, but Southern fish species are flocking to us now. In other words, we need to get used to “Cape Mahi-Mahi.”

Warmer temperatures in New England could extend the growing season for blueberries, strawberries, peaches, and corn. That could be a silver lining for consumers and farmers’ markets.

Food policy is often inherently conservative: organic food fans and proponents of farm subsidies want different versions of the same thing, which is to cling to the way food’s always been. But food is going to change whether we like it or not — and our food policies should try to direct those changes, not stop them.

http://apps.bostonglobe.com/ideas/graphics/2018/11/the-next-bite/the-supply-chain-editorial/

04

May
2018

In Blog
Featured

By admin

60 Minutes: CRISPR: The gene-editing tool revolutionizing biomedical research

On 04, May 2018 | In Blog, Featured | By admin

A new tool could be the key to treating genetic diseases and may be the most consequential discovery in biomedicine this century.

It’s challenging to tell a story about something that’s invisible to the naked eye and tricky to explain. But it’s one we undertook, because rarely does a discovery come along that could revolutionize medicine.  It’s called CRISPR and it stands for Clustered Regularly Interspaced Short Palindromic Repeats. CRISPR sounds more like a refrigerator compartment than a gene-editing tool, but it’s giving scientists power they could only imagine before – to easily edit DNA – allowing them to reprogram the genetic code of living things. That’s opening up the possibility of curing genetic diseases. Some researchers are even using it to try to prevent disease entirely by correcting defective genes in human embryos. We wanted to see for ourselves, so we went to meet a scientist at the center of the CRISPR craze.

“There are about 6,000 or more diseases that are caused by faulty genes. The hope is that we will be able to address most if not all of them.”

Bill Whitaker: This is CRISPR?

Feng Zhang: This has CRISPR in it.

Bill Whitaker: So– this is what’s revolutionizing science and biomedicine?

Feng Zhang: This is what many people are using– in research — and trying to develop treatments.

Bill Whitaker: That’s wild.

Feng Zhang: Yeah.

That little vial is igniting a big revolution that is likely to change the way doctors treat disease in the future. One of the brains behind it, is baby-faced Feng Zhang.

crisprpreview.jpg

Feng Zhang speaks with correspondent Bill Whitaker

 CBS NEWS

At 36, he’s already a tenured professor at MIT and a scientific celebrity because he figured out a way to override human genetic instructions using CRISPR.

Bill Whitaker: So, the CRISPR is not the liquid, the CRISPR is in the–

Feng Zhang: It’s dissolved in the liquid. There are probably billions of molecules of CRISPR…

Bill Whitaker: Billions?

BOTH: In here.

Feng Zhang: That’s right. And the way we use it is we take the liquid and apply it to cells.

For the last seven years, Zhang has been working on CRISPR at the Broad Institute in Cambridge, Massachusetts. It’s a research mecca brimming with some of the brightest scientific minds from Harvard and MIT on a mission to fight disease. CRISPR is making medical research faster, cheaper, easier. Zhang’s colleagues predict it will help them tackle diseases like cancer and Alzheimer’s.  

Bill Whitaker: How many diseases are we talking about that this could be used to treat?

Feng Zhang: There are about 6,000 or more diseases that are caused by faulty genes. The hope is that we will be able to address most if not all of them.

Bill Whitaker: Most if not all of them?

Feng Zhang: That’s the long-term hope.

Bill Whitaker: So we’re talking diseases like Huntington’s—

Feng Zhang: Uh-huh.

Bill Whitaker: Sickle Cell.

Feng Zhang: Yup. ALS—hemophilia.

Eric Lander: I think CRISPR, it’s fair to say, is perhaps the most surprising discovery and maybe most consequential discovery in this century so far.

lander-walk-talk-2.jpg

Eric Lander, director of the Broad Institute, speaks with correspondent Bill Whitaker

 CBS NEWS

To understand exactly what CRISPR is, we went to Eric Lander for a quick science lesson. He’s director of the Broad and Zhang’s mentor. He’s best known for being a leader of the Human Genome Project that mapped out all of our DNA, which is like a recurring sequence of letters.

Eric Lander: During the Human Genome Project, we could read out all the human DNA, and then, in the years afterwards, find the misspellings that caused human diseases. But we had no way to think about how to fix ’em. And then, pretty much on schedule, this mind-blowing discovery that bacteria have a way to fix those misspellings, appears.

Bill Whitaker: This comes from bacteria?

Eric Lander: This comes from bacteria.  Bacteria, you know, they have a problem. And they came up with a real clever solution. When they get infected by viruses, they keep a little bit of DNA, and they use it as a reminder. And they have this system called CRISPR that grabs those reminders and searches around and says, “If I ever see that again, I am gonna cut it.”

Zhang used that same bacterial system to edit DNA in human cells. Our DNA is made up of chemical bases abbreviated by the letters A, T, C, and G. As you can see in this animation from Zhang’s lab at MIT, a mutation that causes disease reads like a typo in those genetic instructions. If scientists can identify the typo, they can program CRISPR to find it and try to correct it.

Bill Whitaker: You program it? You say–

Feng Zhang: That’s right.

Bill Whitaker:  “I’m looking for this string of letters.”

Feng Zhang: Uh-huh.

Bill Whitaker: And the CRISPR will go in, and out of all of the billions and billions and billions of– of letters on your DNA, find the exact ones that you have programmed?

Feng Zhang: That’s right. CRISPR will allow you to– do many different things. You can cut it– to edit it.

Bill Whitaker: So you can snip out the bad part and you can add something that you want as well?

Feng Zhang: That’s right. You can give the cell a new piece of DNA that carries the sequence you want to incorporate into the genome.

Bill Whitaker: You say this so matter of factly. This is amazing.

Feng Zhang: It is pretty cool.

Bill Whitaker: How many other labs around the world are working with CRISPR like this?

Feng Zhang: Many. One of the things that we have been doing is to make the tool available to researchers. To date I think we have gotten it out over– 45,000 times, to 2,200 labs, in 61 countries.

Bill Whitaker: What are they doing with it?

Feng Zhang: They are using it to do everything.  A lot of applications of CRISPR. It’s really a Swiss army knife.

Cue the worldwide CRISPR frenzy. At the University of California, scientists used a form of CRISPR to edit mosquitos so they can’t transmit malaria. Their colleagues are modifying rice to better withstand floods and drought. In China, scientists tweaked a gene in beagles to make them more muscular.

crispr-full.jpg

A CRISPR vial from Zhang’s lab made its way to Dr. Kang Zhang. He is an ophthalmologist and a professor at the University of California, San Diego and wanted to see what all the hype was about.

Bill Whitaker: What did you think when you first heard of CRISPR?

Kang Zhang: I was a little bit skeptical.

Bill Whitaker: Why skeptical?

Kang Zhang: It worked so well. Too well to be believable.

He decided to experiment on mice with retinitis pigmentosa, a genetic form of blindness. He conducted a vision test using a mouse with the disease.

Bill Whitaker: This is the blind mouse?

Kang Zhang: This is the blind mouse. And– obviously, you can see that he is ignoring the rotating stripes.

His researchers injected CRISPR into the eye of another blind mouse. The CRISPR was programmed to find the main gene associated with the disease and turn it off. It takes three months to see the results.

Kang Zhang: Now, let’s see how he’s responding to the light.

Bill Whitaker: He’s following it around.

Kang Zhang: Yes.

Bill Whitaker: Look at that. You’re sure that he is seeing these lights?

Kang Zhang: This is actually a very commonly used test for vision.

Bill Whitaker: How much of their sight do they recover?

Kang Zhang: About 30, sometimes even 50% of the sight for– for mice.

The next phase of Dr. Zhang’s research is to see how CRISPR works on one of our closer relatives. He sent us this video from his lab in China where he’s studying monkeys with retinitis pigmentosa. The blind monkey ignores the food. He says this monkey was treated with CRISPR and it’s easy to see the difference. Dr. Zhang hopes to try this on humans soon.

If CRISPR is used to treat disease or make a drug it could mean big bucks. The Broad and Feng Zhang hold a primary patent for CRISPR’s use in human cells in the United States. But no technology is developed in a vacuum. Biochemist Jennifer Doudna at the University of California, Berkeley and her team made landmark CRISPR discoveries.

This week, they are challenging Zhang and the Broad in court for the rights arguing in part that Zhang’s advance was derived from her team’s breakthrough. It’s a high stakes battle. CRISPR is projected to be a multi-billion dollar market in a decade.

Bill Whitaker: Does that mean big business for you?

Feng Zhang: I think we’re– we’re still– quite a ways away from developing– CRISPR into a real therapeutic.

Bill Whitaker: I think you’re being a little bit modest. I mean this is sparking an incredible boom in biomedicine. And you’re in the center of it.

Feng Zhang: I think there is still really a lot of work that still needs to be done,  developing the systems so that they are efficient enough, making sure that they are safe enough, but these are things that– that we’re working hard to– to make possible.

“While it’s not gonna affect somebody who might be dying of a disease today, this is gonna have a real effect over the course of the next decade and couple of decades.”

But, what if it were possible to stop disease from even occurring? That sounds like science fiction, but a team of researchers in Portland, Oregon say with CRISPR, it’s now a reality.

Bill Whitaker: You correct it at the very, very earliest stages of life.

Shoukhrat Mitalipov: Right.

Bill Whitaker: In the womb.

Shoukhrat Mitalipov: Even before the womb.

Manipulating embryos has been the focus of Shoukhrat Mitalipov’s career. He runs the Center for Embryonic Cell and Gene Therapy at Oregon Health and Science University. Mitalipov is a maverick. He regularly makes headlines with his innovative, sometimes controversial methods to prevent genetic disease.

Shoukhrat Mitalipov: Preventing is always more effective– so there would be no– no recurrence of new disease. Particularly when we’re talking about heritable– diseases that parents pass to children.

So Mitalipov and an international team of scientists decided to use CRISPR on human embryos to correct a single genetic mutation that causes a deadly heart disease called hypertropic cardiomyopathy.

They got healthy eggs from donors and sperm from a man who carries the disease. At the same time the eggs are fertilized, they also get an injection of CRISPR. Mitalipov enlarged the microscopic procedure over three hundred times so we could see it.

Shoukhrat Mitalipov: Here we have our pipette with sperm inside, which has been already exposed to CRISPR.  And this is a egg. And so what we need to do is pierce through, and then we break membrane. And now –

Bill Whitaker: Release the sperm into the egg.

Shoukhrat Mitalipov: Yeah. And now this is the sperm coming in.

Bill Whitaker: Wow.

Shoukhrat Mitalipov: Now it’s inside there.

Bill Whitaker: Just like that, that egg has been CRISPRed?

Shoukhrat Mitalipov: CRISPRed, fertilized.

Bill Whitaker: And you have changed the genetic destiny of that embryo.

Shoukhrat Mitalipov: Yes, we believe so.

These embryos will never be implanted, but they are grown in an incubator for three days and then checked to see if they carry the disease mutation.

Normally, 50 percent would. Mitalipov says with CRISPR, 72 percent were free of the mutation that would cause the heart disease.

Bill Whitaker: This is a huge– advance in science and medicine.

Shoukhrat Mitalipov: We hope so. I think we– we’re still kind of in the early stages. I wouldn’t say that we are ready to– to go to clinics now.

He knows his results have to be replicated by an outside lab before they’re accepted by the scientific community. But if they hold up, one day CRISPR could be used to help families that have been plagued by inherited disease for generations.

Bill Whitaker: Is that what drives you?

Shoukhrat Mitalipov: Yes. Of course, it’s a suffering of children, but also the guilt the parents have at saying, “I passed it to my child.” So it’s like, “I caused this disease.” And I think now, we have a tool where we could help these families.

Mitalipov wants to use CRISPR to eliminate disease, but the concern is his research has created a blueprint for less scrupulous doctors to design human beings – to edit embryos to make babies that are smarter, taller, stronger. Mitalipov says that’s not even possible right now.

Bill Whitaker: Your critics say that you’re playing God.

Shoukhrat Mitalipov: I think– you could say to– to every treatment that they– humans and doctors develop that– we– we’re playing God. God gave us brains so we could find a way to eliminate suffering of human beings. And if that’s– you know, playing God, I guess that’s the way it is.

Bill Whitaker: So what do you think about editing an embryo to prevent disease?

Feng Zhang: We don’t really understand how complicated biology is. There’s a gene called PCSK9. If you remove PCSK9, you can reduce cardiovascular disease, heart attack– risks significantly. But it also has been shown recently to increase risk for diabetes. So how do you make the judgment call between these tradeoffs? And there will likely be other—impacts we haven’t yet identified. So I think we need to wait and be more cautious.

Eric Lander: I don’t think we’re close to ready to use it to go edit the human population. I think we’ve gotta use it for medicine for a while. I think those are the urgent questions. That’s what people want right now, is they want cures for disease.

Those urgent questions might soon be answered. A small clinical trial, the first in the U.S. using CRISPR to target certain types of cancer, is now enrolling patients.

Eric Lander: I wanna always balance hope versus hype here. While it’s not gonna affect somebody who might be dying of a disease today, this is gonna have a real effect over the course of the next decade and couple of decades. And for the next generation, I think it’ll be transformative.

Produced by Nichole Marks. Associate producers, Kate Morris and Jaime Woods.

© 2018 CBS Interactive Inc. All Rights Reserved.

02

Aug
2017

In Blog
Featured

By admin

10 myths about farming to remember on your next grocery run

On 02, Aug 2017 | In Blog, Featured | By admin

Most of us don’t spend our days plowing fields or wrangling cattle. We’re part of the 99 percent of Americans who eat food but don’t produce it. Because of our intimate relationship with food and because it’s so crucial to our health and the environment, people should be very concerned about how it’s produced. But we don’t always get it right. Next time you’re at the grocery store, consider these 10 modern myths about the most ancient occupation. Read more…

07

Jun
2017

In Blog
Featured
GMO’s and The Environment

By admin

5 Things To Know About GMOs This World Environment Day

On 07, Jun 2017 | In Blog, Featured, GMO’s and The Environment | By admin

GMO Answers

Read more…

Latest News

Defense, and SAb Biotherapeutics to Partner to Develop a Novel COVID-19 Therapeutic

April 6, 2020 by admin

Published by Medical Counter Measures

A therapeutic to treat novel coronavirus disease 2019 (COVID-19) is moving forward in development through a partnership between BARDA, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO – CBRND), and SAb Biotherapeutics, Inc. (SAb), of Sioux Falls, South Dakota.

Using an interagency agreement with JPEO’s Medical CBRN Defense Consortium, BARDA transferred approximately $7.2 million in funding to (JPEO – CBRND) to support SAb to complete manufacturing and preclinical studies, with an option to conduct a Phase 1 clinical trial.

Read the full press release here.

Agri-Pulse: Can cows be used to fight coronavirus?

March 30, 2020 by admin

Bovine plasma donors genetically engineered to produce human antibodies are in the front lines of the struggle against coronavirus.

SAB Biotherapeutics, a Sioux Falls, S.D., biotechnology company that has been successfully testing use of antibodies from cows to fight diseases such as another coronavirus, Middle East respiratory syndrome, now is engaged in developing a treatment for COVID-19, the disease caused by the novel coronavirus.

Read the full article here.

Times Argus: High-tech chestnuts: US to consider genetically altered tree

November 7, 2019 by admin

SYRACUSE, N.Y. (AP) — Chestnuts harvested from high branches on a chilly fall morning look typical: they’re marble sized, russet colored and nestled in prickly burs. But many are like no other nuts in nature.

In a feat of genetic engineering, about half the chestnuts collected at this college experiment station feature a gene that provides resistance to blight that virtually wiped out the American chestnut tree generations ago.

Read more here.

Categories